Powerful new tool reveals potential 'goldmine' of cancer targets hidden in 'junk DNA'

A QIMR Berghofer-led research team has created a groundbreaking tool to delve into the enigmatic realm of "junk DNA," commonly referred to as long noncoding RNA (lncRNA). This discovery has unveiled a wealth of molecular potential that could revolutionize precision cancer treatments. Through single-cell and spatial tissue analysis, the scientists identified 219,442 unique lncRNA molecules within various cancer types, including breast, brain, bowel, and skin cancers.

Among these findings were 94,795 previously undocumented lncRNA molecules, many of which exhibited promising functional or otherwise interesting characteristics. By mapping the precise 3D locations of these lncRNA molecules within cancer tissue samples and their associated cells, the researchers were able to reveal the interactions between these molecules and other genes and molecules within tumor environments.

This newfound knowledge allowed the team to predict the likely functional roles of each lncRNA molecule and their potential involvement in cancer growth and spread. The results of this study have been compiled into a comprehensive online resource called SPanC-Lnc, which offers unprecedented spatial detail about lncRNAs in cancer.

The study's lead, Associate Professor Quan Nguyen, expressed pride in solving a long-standing challenge in the field by identifying and understanding the roles of these lncRNA molecules. He emphasized the potential of this "dark matter of the genome" as a goldmine for new cancer biomarkers and therapeutics. Dr. Prakrithi Pavithra, the study's first author and QIMR Berghofer researcher, shared her motivation to discover new cancer-fighting approaches after losing friends to the disease.

She highlighted the importance of understanding the biology of cancer to develop targeted therapies that are effective for individual patients. The researchers now plan to validate these lncRNA discoveries through functional experiments to identify the most promising candidates for potential new diagnostics and treatments. This work has already led to the discovery of a lncRNA molecule that can induce an immune response against a common form of breast cancer, which is being developed into a potential RNA-based therapy.

The collaboration with other researchers at QIMR Berghofer, such as Professor Vicki Whitehall, who leads bowel cancer research, underscores the significance of this breakthrough in the quest for new cancer treatments.